FindTrial
Sign In

STUDY THE EFFICACY AND SIDE EFFECTS OF SUBCUTANEOUS V/S ORAL METHOTREXATE IN THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS AND PALMOPLANTAR PSORIASIS

EFFICACY AND TOLERABILITY OF SUBCUTANEOUS V/S ORAL METHOTREXATE IN THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS AND PALMOPLANTAR PSORIASIS - A HOSPITAL BASED PROSPECTIVE RANDOMIZED CONTROLLED COMPARATIVE STUDY

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/10/028555
Enrollment
50
Registered
2020-10-22
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L409- Psoriasis, unspecified

Interventions

Intervention1: Injection Methotrexate subcutaneous versus Oral methotrexate tablet in patients with chronic plaque psoriasis and palmoplantar psoriasis: Group A: Tablet 0.3-0.5mg/kg body weight/week f

Sponsors

DrPooja
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: a) diagnosed to be suffering from Moderate to Severe Psoriasis and palmoplantar psoriasis or palmoplantar psoriasis clinically in DERMATOLOGY OPD of a tertiary care centre in Karad b) Have completed 18 years of age. c) Have not taken any treatment, two months prior to the inclusion in study.

Exclusion criteria

Exclusion criteria: 1. Hemoglobin 2. Elevation of hepatic enzymes (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) to more than twice the upper limit of normal or any deranged liver function tests. 3. Hepatitis, active or recurrent, cirrhosis or excessive current alcohol intake. 4. Use of other hepatotoxic drugs by the patient 5. Positive hepatitis B, hepatitis C or HIV serology 6. Pulmonary or extra-pulmonary active tuberculosis 7. Deranged renal function test. 8. Pregnancy or lactation or if patient is planning to conceive during the treatment period. 9. Patient on other immunosuppressive drugs 10. Recent live vaccination 11. Unreliable patient 12. Patients unwilling for monthly follow-ups. 13. Patient with known hypersensitivity to drug. 14. Patient with unrealistic expectation

Design outcomes

Primary

MeasureTime frame
Improvement in primary efficacy variables: PASI in chronic plaque psoriasis, m-PASI in palmoplantar psoriasisTimepoint: 7th day, 30th day, 60th, 90th day—

Secondary

MeasureTime frame
Improvement in secondary efficacy variables like VAG,PGA and DLQI in chronic plaque psoriasis, VAG,PGA,PPQOL in palmoplantar psoriasisTimepoint: 7th day, 30th day, 60th, 90th day—

Countries

India

Contacts

Public ContactPooja K H

Krishna institue of medical science, Karad

docmsk2@gmail.com9535420428

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026